USC Scientists Find That Multi-Vitamin Use And Hormone Replacement Therapy MayLower Levels Of Homocysteine

November 11, 1998

DALLAS, Nov. 9, 1998 -- University of Southern California scientists Howard N. Hodis, M.D., Wendy J. Mack, Ph.D., and their colleagues have found intriguing evidence that both regular multi-vitamin use or long-term hormone replacement therapy may reduce cardiovascular damage caused by homocysteine, a mysterious amino acid found in the blood that many believe will emerge as "the cholesterol of the next century."

Hodis, Director of the USC Atherosclerosis Research Unit, and Mack will present these findings Nov. 10 and 11 to colleagues at the American Heart Association's 71st Annual Scientific Conference in Dallas.

Recent research has linked high levels of homocysteine to atherosclerosis, the disease process behind cardiovascular disease - the nation's No. 1 killer. Both reports point to exciting possibilities in the prevention and treatment of atherosclerosis, a build up of fatty tissue in the arteries that results in heart attacks and strokes.

Hodis and his colleagues have been tracking the emergence of homocysteine as a cardiovascular health threat for years. The studies presented at the AHA meeting came out of his ongoing Vitamin E Atherosclerosis Prevention Study (VEAPS), which tracks the thickening of arterial walls (subclinical atherosclerosis) in 353 men and women ages 45 and older. The trial is primarily intended to track the effectiveness of Vitamin E in preventing atherosclerosis.

According to one abstract Hodis presented last week, 190 regular multi-vitamin users in his study had significantly lower homocysteine levels in their blood and their arteries showed less arterial wall thickening than the remaining 161 participants.

In a second abstract, Hodis outlined an intriguing connection between long-term hormone replacement therapy (HRT) and lower homocysteine levels. According to his research, homocysteine levels are lower in women than in men, and, most significantly, levels are lower still in women who had been taking hormone replacement therapy (HRT) for more than seven years.

"These data indicate that total plasma (blood) homocysteine levels are lower in women than in men and that HRT, especially long term HRT use, may play an important role in lowering homocysteine levels," Hodis says.

If the research team's early findings can be confirmed in larger, randomized trials, it brings the intriguing possibility of a relatively simple way to reduce a serious health threat. Using inexpensive multi - vitamins'or more likely a regular intake of folic acids and B-complex vitamins - could reduce atherosclerosis through a lowering of homocysteine levels.

"That's a billion-dollar proposition," Hodis says.
-end-
Dr. Hodis will present his team's research on Hormone Replacement Therapy and Homocysteine at the 71st American Heart Association Meeting in Dallas, Texas
8:30 a.m., Tuesday, November 10, 1998
Room A409/410, Dallas Convention Center

Dr. Hodis will present his team's research on Multi-Vitamin Intake, Homocysteine and Atherosclerosis at the 71st American Heart Association Meeting in Dallas, Texas
10:45 a.m., Wednesday, November 11, 1998
Room A409/410, Dallas Convention Center

RESEARCH EMBARGOED UNTIL TIME OF PRESENTATIONS
Homocysteine and HRT: 8:30 a.m., Tuesday, November 10, 1998
Homocysteine and Multi-vitamins: 10:45 a.m., Tuesday, November 11, 1998
-end-


University of Southern California

Related Atherosclerosis Articles from Brightsurf:

How hormone therapy slows progression of atherosclerosis
As one of the most common treatments for effectively managing menopause symptoms, hormone therapy (HT) is also known to provide multiple health benefits, including slowing the progression of atherosclerosis.

T cells can shift from helping to harming in atherosclerosis
At La Jolla Institute for Immunology (LJI) researchers are dedicated to finding a way to stop plaques from forming in the first place.

New nanoparticle drug combination for atherosclerosis
Physicochemical cargo-switching nanoparticles (CSNP) designed by KAIST can help significantly reduce cholesterol and macrophage foam cells in arteries, which are the two main triggers for atherosclerotic plaque and inflammation.

Atherosclerosis -- How a microRNA protects vascular integrity
Ludwig-Maximilian-Universitaet (LMU) in Munich researchers have discovered a hitherto unknown molecular function of a specific microRNA that preserves integrity of the endothelium and reduces the risk of atherosclerosis.

Atherosclerosis progresses rapidly in healthy people from the age of 40
A CNIC study published in JACC demonstrates that atheroma plaques extend rapidly in the arteries of asymptomatic individuals aged between 40 and 50 years participating in the PESA-CNIC-Santander study.

Scaling up a nanoimmunotherapy for atherosclerosis through preclinical testing
By integrating translational imaging techniques with improvements to production methods, Tina Binderup and colleagues have scaled up a promising nanoimmunotherapy for atherosclerosis in mice, rabbits and pigs -- surmounting a major obstacle in nanomedicine.

Bladder drug linked to atherosclerosis in mice
A drug used in the treatment of overactive bladder can accelerate atheroclerosis in mice, researchers at Karolinska Institutet in Sweden report in a study published in the Proceedings of the National Academy of Sciences (PNAS).

A new therapeutic target for blocking early atherosclerosis in progeria
Researchers at the Centro Nacional de Investigaciones Cardiovasculares and the Universidad de Oviedo have discovered a new molecular mechanism involved in the premature development of atherosclerosis in mice with Hutchinson-Gilford progeria syndrome.

Protective mechanism against atherosclerosis discovered
Immune cells promoting inflammation play a crucial role in the development of atherosclerosis.

Atherosclerosis: Stopped on time
For the first time, LMU researchers are pointing out the influence of the internal clock on atherosclerosis.

Read More: Atherosclerosis News and Atherosclerosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.